1) Acute Skin Toxicity Following Stereotactic Body Radiation Therapy for Stage I Non–Small-Cell Lung Cancer: Who’s at Risk? Bradford S. Hoppe, Benjamin Laser, Alex V. Kowalski, Sandra C. Fontenla, Elizabeth Pena-Greenberg, Ellen D. Yorke, D. Michael Lovelock, Margie A. Hunt, Kenneth E. Rosenzweig. International Journal of Radiation Oncology Biology Physics. 2008; 72(5):1283-1286.

2) Blinded assessment of radiological changes after stereotactic ablative radiotherapy (SABR) for early-stage lung cancer: Local recurrences versus fibrosis.  Suresh Senan, Kitty Huang, Sashendra Senthi, Femke Spoelstra, Andrew Warner, Ben J. Slotman, and David Palma. ASCO MEETING ABSTRACTS Jun 17, 2013:7520.

3) Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites
Jeffrey A. Forquer, Achilles J. Fakiris, Robert D. Timmerman, Simon S. Lo. Radiotherapy and Oncology. 2009;93(3): 408-413.

4) Development and Validation of a Standardized Method for Contouring the Brachial Plexus: Preliminary Dosimetric Analysis Among Patients Treated With IMRT for Head-and-Neck Cancer. William H. Hall, M.D., Michael Guiou, Ph.D., Nancy Y. Lee, M.D., Arthur Dublin, M.D., Samir Narayan, M.D., Srinivasan Vijayakumar, M.D., James A. Purdy, Ph.D., Allen M. Chen. International Journal of Radiation Oncology Biology Physics. 2008;72(5):1362-1367.

5) Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases. Kyle E. Rusthoven, Brian D. Kavanagh, Stuart H. Burri, Changhu Chen, Higinia Cardenes, Mark A. Chidel, Thomas J. Pugh, Madeleine Kane, Laurie E. Gaspar and Tracey E. Schefter. Journal of Clinical Oncology. 2009;27(10): 1579-1584.

6) A novel modified dynamic conformal arc technique for treatment of peripheral lung tumors using stereotactic body radiation therapy. Christopher C. Ross, John J. Kim, Zhe J. Chen, David J. Grew, et al. Practical Radiation Oncology. 2011;1(2): 126-134.

7) Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904 . Jeffrey A. Bogart, Lydia Hodgson, Stephen L. Seagren, A. William Blackstock, Xiaofei Wang, Robert Lenox, Andrew T. Turrisi III, John Reilly, Ajeet Gajra, Everett E. Vokes, and Mark R. Green. Journal of Clinical Oncology. 2010;28(2):202-206.

8) Prediction of Chest Wall Toxicity From Lung Stereotactic Body Radiotherapy (SBRT). Kevin L. Stephans, Toufik Djemil, Rahul D. Tendulkar, Cliff G. Robinson, et al.   International Journal of Radiation Oncology Biology Physics. 2012; 82(2):974-980.

9)  Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). Dunlap NE. Larner JM. Read PW. Kozower BD. Lau CL. Sheng K. Jones DR. Journal of Thoracic & Cardiovascular Surgery. 140(3):583-9, 2010 Sep.

10) Stereotactic Body Radiation Therapy: The Report of AAPM Task Group 101. Benedict, H, Stanley. Medical Physics. 2010 Aug. 37(8): 4078-4101.

11) Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II Study. Achilles J. Fakiris, Ronald C. McGarry, Constantin T. Yiannoutsos, Lech Papiez, et al. International Journal of Radiation Oncology Biology Physics. 2009; 75(3): 677-682.

12) Stereotactic body radiation therapy for inoperable early stage lung cancer. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. JAMA. 2010;303(11):1070-6.

13) Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Chuong MD. Springett GM. Freilich JM. Park CK. Weber JM. Mellon EA. Hodul PJ. Malafa MP. Meredith KL. Hoffe SE. Shridhar R. International Journal of Radiation Oncology, Biology, Physics. 2013; 86(3):516-22.